Development of Enabling Technologies for Energy-Saving Proposals
First written in FY2016. 23 of 33 entries say "Restated". Latest entry: FY2026.
0 other companies' latest entry also says "Other".
- FY2026Update on R&D expenses and research themesAnnual report
「During the consolidated fiscal year, research and development activities focused on developing analytical and evaluation technologies for highly potent pharmaceuticals and other products serving special environments, such as large hospitals and pharmaceutical plants, as well as technologies for maintaining and managing clean environments. Total research and development expenses related to these activities were ¥25 million.」
The Group continued developing analytical and evaluation technologies and clean-environment maintenance and management technologies for special environments, and research and development expenses increased from ¥21 million in the previous fiscal year to ¥25 million. - FY2026-H1Interim R&D Expense UpdateAnnual report
「The total research and development expenses incurred across the Group during the interim consolidated accounting period were ¥15 million. There were no material changes in the status of the Group's research and development activities during the interim consolidated accounting period.」
The disclosure states that there were no material changes in research and development activities and that total research and development expenses for the interim consolidated accounting period were ¥15 million. - FY2025Update to R&D ExpensesAnnual report
「During the consolidated fiscal year, research and development activities focused on developing analytical and evaluation technologies for highly potent pharmaceuticals and other products serving special environments, such as large hospitals and pharmaceutical plants, as well as technologies for maintaining and managing clean environments. Total research and development expenses related to these activities were ¥21 million.」
The Group continued developing analytical and evaluation technologies and clean-environment maintenance and management technologies for special environments, and recorded research and development expenses of ¥21 million. - FY2025-H1Interim R&D Expense UpdateAnnual report
「The total research and development expenses incurred across the Group during the interim consolidated accounting period were ¥10 million. There were no material changes in the status of the Group's research and development activities during the interim consolidated accounting period.」
The disclosure states that there were no material changes in research and development activities and that total research and development expenses for the interim consolidated accounting period were ¥10 million. - FY2024-Q3Update to R&D expenses for the first 3 quartersAnnual report
「The total research and development expenses incurred across the Group during the nine-month period ended the third quarter were ¥24 million. There were no material changes in the status of the Group's research and development activities during the nine-month period ended the third quarter.」
The disclosure states that there were no material changes in research and development activities and that total research and development expenses for the nine-month period ended the third quarter were ¥24 million. - FY2024-Q2Second-quarter R&D expenses updatedAnnual report
「The total research and development expenses incurred across the Group during the six-month period ended the second quarter were ¥15 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
The disclosure states that there were no material changes in research and development activities and that total research and development expenses for the six-month period ended the second quarter were ¥15 million. - FY2024-Q1First-quarter R&D expenses updatedAnnual report
「The total research and development expenses incurred across the Group during the three-month period ended the first quarter were ¥5 million. There were no material changes in the status of the Group's research and development activities during the three-month period ended the first quarter.」
The disclosure states that there were no material changes in research and development activities and that total research and development expenses for the three-month period ended the first quarter were ¥5 million. - FY2023Update on R&D expenses and research themesAnnual report
「During the consolidated fiscal year, research and development activities focused on developing analytical and evaluation technologies for highly potent pharmaceuticals and other products serving special environments, such as large hospitals and pharmaceutical plants, as well as technologies for maintaining and managing clean environments. Total research and development expenses related to these activities were ¥16 million.」
The Group developed analytical and evaluation technologies and clean-environment maintenance and management technologies for special environments, including large hospitals and pharmaceutical plants, and recorded research and development expenses of ¥16 million. - FY2023-Q3Update to R&D expenses for the first 3 quartersAnnual report
「The total research and development expenses incurred across the Group during the nine-month period ended the third quarter were ¥11 million. There were no material changes in the status of the Group's research and development activities during the nine-month period ended the third quarter.」
The disclosure states that there were no material changes in research and development activities and that total research and development expenses for the nine-month period ended the third quarter were ¥11 million. - FY2023-Q2RestatedAnnual report
「The total research and development expenses incurred across the Group during the six-month period ended the second quarter were ¥7 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
The disclosure states that there were no material changes in research and development activities and that total research and development expenses for the six-month period ended the second quarter were ¥7 million. - FY2023-Q1RestatedAnnual report
「The total research and development expenses incurred across the Group during the three-month period ended the first quarter were ¥3 million. There were no material changes in the status of the Group's research and development activities during the three-month period ended the first quarter.」
The disclosure states that there were no material changes in research and development activities and that total research and development expenses for the three-month period ended the first quarter were ¥3 million. - FY2022-Q3RestatedAnnual report
「The total research and development expenses incurred across the Group during the nine-month period ended the third quarter were ¥10 million. There were no material changes in the status of the Group's research and development activities during the nine-month period ended the third quarter.」
The disclosure states that there were no material changes in research and development activities and that total research and development expenses for the nine-month period ended the third quarter were ¥10 million. - FY2022-Q2RestatedAnnual report
「The total research and development expenses incurred across the Group during the six-month period ended the second quarter were ¥6 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
The disclosure states that there were no material changes in research and development activities and that total research and development expenses for the six-month period ended the second quarter were ¥6 million. - FY2022-Q1RestatedAnnual report
「The total research and development expenses incurred across the Group during the three-month period ended the first quarter were ¥3 million. There were no material changes in the status of the Group's research and development activities during the three-month period ended the first quarter.」
The disclosure reconfirms that there were no material changes in research and development activities and states that total research and development expenses for the three-month period ended the first quarter were ¥3 million. - FY2021RestatedAnnual report
「During the consolidated fiscal year, research and development activities focused on environmental assessments for highly potent pharmaceutical facilities and other facilities serving special environments, such as large hospitals and pharmaceutical plants, as well as the development of technologies for maintaining and managing clean environments.」
The Group continued environmental assessment and clean-environment maintenance and management technology development for special environments, including large hospitals and pharmaceutical plants, and reported total research and development expenses of ¥9 million. - FY2021-Q3RestatedAnnual report
「The total research and development expenses incurred across the Group during the nine-month period ended the third quarter were ¥6 million. There were no material changes in the status of the Group's research and development activities during the nine-month period ended the third quarter.」
The disclosure reconfirms that there were no material changes in research and development activities and states that total research and development expenses for the nine-month period ended the third quarter were ¥6 million. - FY2021-Q2RestatedAnnual report
「The total research and development expenses incurred across the Group during the six-month period ended the second quarter were ¥4 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
The disclosure reconfirms that there were no material changes in research and development activities and states that total research and development expenses for the six-month period ended the second quarter were ¥4 million. - FY2021-Q1RestatedAnnual report
「The total amount of research and development activities conducted across the Group during the three-month period ended the first quarter was ¥1 million. There were no material changes in the status of the Group's research and development activities during the three-month period ended the first quarter.」
The company reconfirms that there were no material changes in R&D activities and states that total R&D expenses for the first quarter were ¥1 million. - FY2020RestatedAnnual report
「During the consolidated fiscal year, research and development activities focused on environmental assessments for highly potent pharmaceutical facilities and other facilities serving special environments, such as large hospitals and pharmaceutical plants, as well as the development of technologies for maintaining and managing clean environments. Total research and development expenses related to these activities were ¥14 million.」
The Group continued environmental assessment and clean-environment maintenance and management technology development for special environments, including large hospitals and pharmaceutical plants, and reported research and development expenses of ¥14 million for the fiscal year. - FY2020-Q3RestatedAnnual report
「The total research and development expenses incurred across the Group during the nine-month period ended the third quarter were ¥10 million. There were no material changes in the status of the Group's research and development activities during the nine-month period ended the third quarter.」
The disclosure reconfirms that there were no material changes in research and development activities and states that total research and development expenses for the nine-month period ended the third quarter were ¥10 million. - FY2020-Q2RestatedAnnual report
「The total research and development expenses incurred across the Group during the six-month period ended the second quarter were ¥7 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
The disclosure reconfirms that there were no material changes in research and development activities and states that total research and development expenses for the six-month period ended the second quarter were ¥7 million. - FY2020-Q1RestatedAnnual report
「The total amount of research and development activities conducted across the Group during the three-month period ended the first quarter was ¥3 million. There were no material changes in the status of the Group's research and development activities during the three-month period ended the first quarter.」
The disclosure reconfirms that there were no material changes in research and development activities and states that total research and development expenses for the three-month period ended the first quarter were ¥3 million. - FY2019RestatedAnnual report
「During the consolidated fiscal year, research and development activities focused on environmental assessments for highly potent pharmaceutical facilities and other facilities serving special environments, such as large hospitals and pharmaceutical plants, as well as the development of technologies for maintaining and managing these environments.」
The Group continued environmental assessment and environmental maintenance and management technology development for special environments, including large hospitals and pharmaceutical plants. Research and development expenses were ¥11 million. - FY2019-Q3RestatedAnnual report
「The total amount of research and development activities conducted across the Group during the nine-month period ended the third quarter was ¥8 million. There were no material changes in the status of the Group's research and development activities during the nine-month period ended the third quarter.」
The disclosure reconfirms that there were no material changes in research and development activities and states that total research and development expenses for the nine-month period ended the third quarter were ¥8 million. - FY2019-Q2RestatedAnnual report
「The total amount of research and development activities conducted across the Group during the six-month period ended the second quarter was ¥5 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
The disclosure reconfirms that there were no material changes in research and development activities and states that total research and development expenses for the six-month period ended the second quarter were ¥5 million. - FY2019-Q1RestatedAnnual report
「The Group’s total R&D expenditure for the three-month period ended [the first quarter] was ¥2 million. There were no material changes in the status of the Group’s R&D activities during the three-month period ended [the first quarter].」
The disclosure reconfirms that there were no material changes in research and development activities and states that total research and development expenses for the three-month period ended the first quarter were ¥2 million. - FY2018RestatedAnnual report
「During the consolidated fiscal year, research and development activities focused on environmental assessments for highly potent pharmaceutical facilities and other facilities serving special environments, such as large hospitals and pharmaceutical plants, as well as the development of technologies for maintaining and managing these environments. Total research and development expenses related to these activities were ¥10 million.」
The Group continued environmental assessment and environmental maintenance and management technology development for special environments, including large hospitals and pharmaceutical plants, and reported research and development expenses of ¥10 million for the fiscal year. - FY2018-Q3RestatedAnnual report
「The total amount of research and development activities conducted across the Group during the nine-month period ended the third quarter was ¥7 million. There were no material changes in the status of the Group's research and development activities during the nine-month period ended the third quarter.」
The disclosure reconfirms that there were no material changes in research and development activities and states that total research and development expenses for the nine-month period ended the third quarter were ¥7 million. - FY2018-Q2RestatedAnnual report
「The total amount of research and development activities conducted across the Group during the six-month period ended the second quarter was ¥5 million. There were no material changes in the status of the Group's research and development activities during the six-month period ended the second quarter.」
The disclosure reconfirms that there were no material changes in research and development activities and states that total research and development expenses for the six-month period ended the second quarter were ¥5 million. - FY2018-Q1RestatedAnnual report
「The Group’s total R&D expenditure for the three-month period ended [the first quarter] was ¥2 million. There were no material changes in the status of the Group’s R&D activities during the three-month period ended [the first quarter].」
The Company reconfirmed that there were no material changes in its R&D activities and disclosed total R&D expenses of ¥2 million for the quarter. - FY2017RestatedAnnual report
「During the consolidated fiscal year, the Company conducted R&D on the development of elemental technologies for energy-saving proposals, continuing from the previous consolidated fiscal year. Total R&D expenses related to this work were ¥12 million.」
The Company continues to enhance and improve the efficiency of diagnostic technologies for large medical facilities, factories, and other sites, and to develop energy-saving proposal technologies. - FY2017-Q3RestatedAnnual report
「The Group’s total R&D expenditure for the nine-month period ended [the third quarter] was ¥9 million. There were no material changes in the status of the Group’s R&D activities during the nine-month period ended [the third quarter].」
The Company reconfirmed that there were no material changes in its R&D activities and disclosed total R&D expenses of ¥9 million for the nine-month period. - FY2016First statedAnnual report
「During the consolidated fiscal year, the Company conducted R&D on the development of elemental technologies for energy-saving proposals, continuing from the previous consolidated fiscal year.」
The Company is developing energy-saving proposal technologies based on a policy of enhancing and improving the efficiency of facility maintenance, management, and diagnostic technologies for large medical facilities, factories, and other sites. R&D expenses were ¥11 million.